Evidence map›Paper›PMID 40274624›Full record

ArticleCancer immunology, immunotherapy : CII2025

USP5 motivates immunosuppressive microenvironment in multiple myeloma by activating STAT2-PFKFB4-mediated glycolysis.

Shifeng Long, Ting Ding, Yongliang Zheng, Jinmei Shao, Yan Liu, Qinglan Wang

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shifeng LongDepartment of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, Jiangxi Province, People's Republic of China. longshifeng1910@163.com.
Ting DingDepartment of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, Jiangxi Province, People's Republic of China.
Yongliang ZhengDepartment of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, Jiangxi Province, People's Republic of China.
Jinmei ShaoDepartment of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, Jiangxi Province, People's Republic of China.
Yan LiuDepartment of Transfusion Medicine, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, Jiangxi Province, People's Republic of China.
Qinglan WangDepartment of Transfusion Medicine, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, Jiangxi Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlycolysis, a classic characteristic of cancer cells, can drive cancer progression by generating lactate, which play as a key immunosuppressive mediator. Currently, ubiquitin-specific proteases 5 (USP5) has been demonstrated to facilitate tumor cell survival in multiple myeloma (MM), whereas whether USP5 was involved in glycolysis-lactate production pathway and immunosuppressive microenvironment formation in MM remain unknown.

methodsThe gene and protein expression characteristics were assessed via qRT-PCR and western blot. MM cell survival was determined by CCK-8 and flow cytometry analysis. Glycolysis was evaluated by examining glucose uptake, lactate production and ATP level via corresponding kits. Tumor-associated macrophages polarization was tested via measurement of M1/M2-like macrophage markers using qRT-PCR and flow cytometry methods. Dual-luciferase reporter, chromatin immunoprecipitation and co-immunoprecipitation assays were conducted to verified molecular relationship. Xenograft model was used for verified cellular findings.

resultsUSP5 was abnormally overexpressed in MM patients and cell lines. Knockdown of USP5 could restrain MM cell survival and glycolysis activity, thus reducing lactate-mediated immunosuppressive M2-like macrophage polarization in vitro and in vivo, whereas overexpression of USP5 play opposite impacts. Mechanistically, USP5 could downregulate the ubiquitination modification of STAT to stabilize STAT2 protein, thus activating PFKFB4 transcription. Moreover, STAT2 could overturn the regulatory role of USP5 on MM cell survival, glycolysis and lactate-mediated immunosuppressive M2-like macrophage polarization.

conclusionThese findings elucidated that USP5 served as a regulator of glycolysis-lactate to stimulate M2-like macrophage formation by regulating STAT2-PFKFB4 signaling, which supported that USP5 could be a viable therapeutic target of MM treatment.

Indexed as

GlycolysisMultiple MyelomaTumor MicroenvironmentUbiquitin-Specific ProteasesAnimalsCell Line, TumorFemaleHumansMacrophagesMaleMiceMice, Inbred BALB CMice, NudeTumor-Associated MacrophagesUbiquitin-Specific ProteasesGlycolysisMacrophage polarizationMultiple myelomaUSP5

Identifiers

PMID40274624
PMCPMC12022197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.